PAVmed Inc. Q3 2026 Earnings Call Summary Moby Intelligence Fri, November 13, 2026 at 1:00 PM EST 4 min read NVDA -3.13% PAVM +21.73% LCID -7.55% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Securing Medicare reimbursement for EsoGuard is described as a transformational milestone, shifting Lucid's commercial strategy to aggressively target the Medicare population through claim-by-claim adjudication.
Veris enrollment at the James Cancer Center nearly doubled between July and September, driven by the expansion of the clinical rollout across most oncology departments and improved EHR integration.
Management is leveraging the Ohio State engagement as a strategic laboratory to optimize clinical workflows and reduce onboarding friction, creating a template for future commercial scaling.
The regulatory strategy for PortIO has shifted toward a potential 510(k) pathway, as management believes excluding emergency use from the label may allow for a shorter, less capital-intensive approval process.
Octeris is positioned as a disruptive imaging alternative to current molecular tests, aiming to provide real-time assessment of esophageal dysplasia to guide immediate biopsy and treatment decisions.
Financial results were heavily impacted by a $10 million non-cash mark-to-market adjustment related to the decline in Lucid's share price, which also triggered a temporary debt covenant breach.
The Veris implantable physiologic monitor is on track for an FDA 510(k) submission in early 2027, with the app design freeze and skin validation study expected by year-end 2026, while the 90-day GLP animal study initiated in October continues toward the early 2027 FDA submission.
Lucid plans to scale its commercial infrastructure aggressively but responsibly to capture the revenue opportunity presented by consistent Medicare payments.
A formal pre-submission meeting with the FDA for PortIO in January will be the critical determinant for the device's regulatory pathway and associated capital requirements.
Octeris clinical validation study enrollment is scheduled to begin in January at the University of North Carolina following the completion of the next-generation probe design.
Management expects the Veris 1,000-patient registry at Ohio State to be completed by the end of the first quarter of 2027, providing the data necessary for broader commercialization.
The company did not satisfy a collateral coverage covenant on its $15 million senior secured note due to Lucid's share price decline; however, the noteholder has waived this through the SEC filing date.
A $10 million non-cash mark-to-market adjustment on Lucid shares was the single largest item impacting the third-quarter profit and loss statement.
PAVmed established a new $9.4 million at-the-market (ATM) facility in September, which remains fully available to support ongoing operations and R&D efforts.
The company holds approximately $32.5 million in potential future cash inflows from warrants, including $30 million in out-of-the-money Series D warrants and $2.5 million in Veris warrants that could be called upon FDA clearance of the Veris implantable device.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management attributed the growth to the steady rollout across over a dozen individualized cancer departments and strong buy-in from hospital leadership.
The focus is on learning how to insert the platform into complex workflows to minimize friction before a broader commercial 'rinse and repeat' strategy.
While receiving interest from other centers, PAVmed is intentionally focusing on OSU to build 'institutional knowledge' and a 1,000-patient registry.
The goal is to have a proven template ready for full commercialization once the implantable monitor acts as a 'force multiplier' for the platform's value.
Management believes successful first-in-human data and a refined 'intended use' that excludes emergency insertion may support a 510(k) pathway.
A 510(k) designation would result in a shorter timeline and lower capital requirements compared to the previously assumed De Novo route.
Octeris aims to make molecular risk-stratification tests obsolete by using advanced imaging to measure cell nuclei size during endoscopy.
The long-term goal is a 'one-time procedure' where endoscopists can identify and ablate abnormal cells on the spot, eliminating multiple interventional steps.
